Neutral
●
Business Wire
●
5 months ago
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced an expanded, multi-year collaboration with Gilead Sciences, Inc. (Nasdaq: GILD) aimed at building and advancing Gilead's oncology pipeline. To date, Gilead has leveraged Tempus' extensive repository of de-identified multimodal data to inform a r...